TABLE 1.
Plasmids used in this study
| Plasmid | Insert | Determinantsa | Source or reference |
|---|---|---|---|
| pBluescript II KS | Ampr, β-gal | Stratagene | |
| pKS-SSP-2 | Wild-type ssp-2 | Ampr, β-gal | This study |
| pBluescript II Sk | Ampr | Stratagene | |
| pMOhly1 | Ampr, Hly | 12 | |
| pSK-2023 | Wild-type ssp-2 | Ampr | This study |
| pSK-2123 | ssp-2 with 5′deletion | Ampr | This study |
| pSK-2027 | ssp-2 with 3′deletion | Ampr | This study |
| pSK-3027 | ssp-2 with 5′ and 3′deletions | Ampr | This study |
| pMO-2023 | Wild-type ssp-2 | Hly, Ampr | This study |
| pMO-2123 | ssp-2 with 5′deletion | Hly, Ampr | This study |
| pMO-2027 | ssp-2 with 3′deletion | Hly, Ampr | This study |
| pMO-3027 | ssp-2 with 5′ and 3′ deletions | Hly, Ampr | This study |
| VR2519 | Wild-type ssp-2 preceded by the translation initiation complex and leader peptide sequences of human tissue plasminogen activator. | Kmr | 17 |
a
β-gal, β-galactosidase.